Aimmune Therapeutics Inc. (NASDAQ:AIMT)‘s stock had its “outperform” rating reissued by analysts at Wedbush in a report released on Thursday. They currently have a $42.00 price objective on the stock. Wedbush’s price objective would suggest a potential upside of 64.71% from the stock’s current price.

Other research analysts have also recently issued research reports about the company. Credit Suisse Group AG reissued a “buy” rating and issued a $35.00 price objective on shares of Aimmune Therapeutics in a research report on Friday, August 19th. Zacks Investment Research cut Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 19th. JMP Securities started coverage on Aimmune Therapeutics in a research report on Monday, September 26th. They issued an “outperform” rating and a $30.00 price objective on the stock. Finally, Piper Jaffray Cos. restated an “overweight” rating and issued a $38.00 target price on shares of Aimmune Therapeutics in a research note on Friday, September 23rd. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $32.20.

Analyst Recommendations for Aimmune Therapeutics (NASDAQ:AIMT)

Shares of Aimmune Therapeutics (NASDAQ:AIMT) opened at 25.50 on Thursday. The firm’s market capitalization is $1.08 billion. Aimmune Therapeutics has a 1-year low of $9.77 and a 1-year high of $26.27. The company has a 50-day moving average price of $17.27 and a 200 day moving average price of $14.39.

In related news, insider Mary M. Rozenman sold 30,000 shares of the business’s stock in a transaction on Thursday, September 8th. The stock was sold at an average price of $16.80, for a total transaction of $504,000.00. Following the sale, the insider now directly owns 30,000 shares in the company, valued at approximately $504,000. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Mary M. Rozenman sold 24,096 shares of the business’s stock in a transaction on Friday, November 4th. The shares were sold at an average price of $17.60, for a total value of $424,089.60. Following the sale, the insider now owns 24,096 shares in the company, valued at $424,089.60. The disclosure for this sale can be found here. 24.56% of the stock is owned by company insiders.

Several hedge funds have recently added to or reduced their stakes in AIMT. TLP Group LLC raised its stake in Aimmune Therapeutics by 0.6% in the second quarter. TLP Group LLC now owns 2,833,285 shares of the company’s stock worth $30,656,000 after buying an additional 17,000 shares during the last quarter. Eagle Asset Management Inc. raised its stake in Aimmune Therapeutics by 7.4% in the third quarter. Eagle Asset Management Inc. now owns 2,136,090 shares of the company’s stock worth $32,041,000 after buying an additional 147,656 shares during the last quarter. Vanguard Group Inc. raised its stake in Aimmune Therapeutics by 8.9% in the second quarter. Vanguard Group Inc. now owns 1,339,847 shares of the company’s stock worth $14,497,000 after buying an additional 109,457 shares during the last quarter. Pictet Asset Management Ltd. raised its stake in Aimmune Therapeutics by 798.5% in the second quarter. Pictet Asset Management Ltd. now owns 831,093 shares of the company’s stock worth $12,757,000 after buying an additional 738,593 shares during the last quarter. Finally, Alliancebernstein L.P. raised its stake in Aimmune Therapeutics by 16.5% in the second quarter. Alliancebernstein L.P. now owns 742,217 shares of the company’s stock worth $8,031,000 after buying an additional 105,246 shares during the last quarter. Institutional investors own 70.49% of the company’s stock.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc, formerly Allergen Research Corporation, is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

5 Day Chart for NASDAQ:AIMT

Receive News & Stock Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related stocks with our FREE daily email newsletter.